The Readout Loud STAT

Our Washington correspondent Sarah Owermohle joins us to talk about how JD Vance, Donald Trump's newly announced running mate, could influence health policy if Trump wins the election. We also discuss the latest news in the biopharma industry, including the latest developments in the ongoing controversy surrounding Cassava’s Alzheimer’s drug, shortages of insulin as Novo Nordisk and Eli Lilly turn their focus toward GLP-1 drugs, and a shakeup in leadership at Gilead.

STAT's West Coast biotech reporter Jonathan Wosen joins "The Readout LOUD" to discuss what’s driving workforce cuts. Plus, entrepreneurs Alexis Borisy and Zach Weinberg call in to discuss their biotech incubator Curie.Bio and how they hope to “free the founders.” We also discuss a big change in Pfizer’s leadership and the debate over a new side effect tied to the diabetes drug Ozempic.

STAT health tech reporter Brittany Trang guest co-hosts "The Readout LOUD" this week, where we discuss AI for drug development, the latest in the H5N1 bird flu outbreak, a surprise entrant to the GLP-1 field, and more news in the life sciences. And STAT chief Washington correspondent Rachel Cohrs Zhang joins the podcast to talk about a new proposal for obesity drug coverage in Washington and what to expect from the first presidential debate.

STAT reporter Jason Mast joins us to discuss Anthony Fauci's memoir "On Call," which was published this week. Hosts Allison DeAngelis and Adam Feuerstein also dissect Alnylam's forthcoming clinical trial data and take stock of how the biotech markets are succeeding and potentially falling flat midway through the year.
For more on Fauci's memoir "On Call," go here; for Adam's primer on Alnylam's ATTR-CM trial, go here; read about BridgeBio's plans here; and for more on biotech startup financing, go here.

STAT's Nicholas Florko joins to explain what it means to be a reporter writing about the commercial determinants of health. Hint: Florko's most recent stories focus on weed, vapes, and raw milk. And instead of being chained to a desk, he often drives around to convenience stores and buy bad stuff — all in the name of good journalism. But first, co-hosts Adam Feuerstein and Allison DeAngelis chat about Pfizer's Duchenne gene therapy setback, the likely approval of a new treatment for Alzheimer's disease, and Bob Langer's most recent startup.

STAT colleague Meghana Keshavan joins us to dissect Lykos Therapeutics' meeting with an FDA advisory committee. We also discuss the latest news in the health and life sciences, including stories from major biotech conferences.
To learn more about Lykos' advisory committee meeting, go here; for more on the tumult at BIO, go here; for a recap of ASCO, go here; to read the latest on Novartis' acquisition of MorphoSys, go here. And you can sign up for Adam’s new newsletter, Biotech Scorecard, here.